Patients with unresectable, liver-confined intrahepatic cholangiocarcinoma treated with HAIP chemotherapy showed notable outcomes.

• Median overall survival was 26 months; 3-year survival rate was 28%, and 5-year survival rate was 15%.
• Partial response on imaging was achieved in 53% of patients, with a disease control rate of 96%.

Consider HAIP chemotherapy for selected patients, particularly since multifocal disease and tumor size may impact outcomes significantly.

A nationwide protocol led to significantly increased resection rates for locally advanced pancreatic cancer (LAPC) in the Netherlands, improving potential long-term survival.

• Resection rates jumped to 86%, nearly three times the expected number.
• In-hospital major morbidity was 44%, while mortality was just 0.6%, both within safety benchmarks.

Implementing international best practices is feasible and could enhance outcomes for selected LAPC patients.

• Extended resections were common, with 77% of patients undergoing complex procedures.

A study reveals stark differences in hepatocellular carcinoma outcomes between South Africa and Sweden, highlighting the need for region-specific treatment protocols.

• Patients in South Africa were significantly younger (median 50 vs. 71 years) and had more advanced disease.
• Only 9.2% received curative treatments in South Africa versus 42.5% in Sweden.

Survival rates were drastically lower: 1-year survival was 17.8% in South Africa compared to 58.9% in Sweden.

Tailored clinical guidelines are crucial to improve patient outcomes in lower-income regions.

Robotic liver resection is safe and shows better outcomes as surgeons gain experience.

• Operative time decreases significantly after 62 cases, from 240 to 220 minutes.
• Progress to mastery increases textbook outcomes from 76% to 87%.

High complexity cases still meet benchmark standards, indicating robust performance.

• Major complications plateau at 9% during proficiency, with low conversion rates (2%) and stable 90-day mortality (0.7%).

Histopathologic response predicts better survival in pancreatic cancer patients despite imaging showing stable or progressive disease.

• 89% of patients completed neoadjuvant therapy; 73% underwent resection.
• Radiographic response was low: 27% had tumor regression, while 66% had stable disease.
• 83% achieved significant serum CA 19-9 reduction, and 74% showed histopathologic response after resection, including 8% with complete response.

Histopathologic outcomes are vital for predicting long-term survival and should inform surgical decision-making.